The Bristol Myers Squibb Antibiotic Tequin can Cause Serious Diabetes, Says Study
March 1, 2006
Reuters released a story today about the potential “life threatening” side effects of Bristol Myers’ pharmaceutical drug Tequin, according to a Canadian study.
The news was to be published by The New England Journal of Medicine at the end of March, but Reuters got the scoop early because of the seriousness of the charges.
Among the findings of this study, it was found that seniors taking Tequin (also known by the generic name Gatifloxacin) “were 17 times more likely to develop serious diabetes than if they took another antibiotic,” Reuters reported.
The elderly were also four times more likely to be taken to the hospital for hypoglycemia, according to the study.
So far there has been no word from the Food and Drug Administration, but US Recall News stays up-to-date on FDA recalls. Click here for our FDA Recall feed.
US Recall News made no attempt to contact the pharmaceutical drug company Bristol Myers, and cannot confirm the accuracy of the study mentioned on this page.
Click here to read the full story at Reuters.
Were you affected? Click Here for a free case evaluation!
Comments
2 Responses to “The Bristol Myers Squibb Antibiotic Tequin can Cause Serious Diabetes, Says Study”
Have something to share?

FDA Evaluates New Studies on Risk of Birth Control Medications Like Yaz
States Press for Fruity Malt Liquor Recall of Blast by Snoop Dog and Pabst
Survey: Consumers Want More Prompt Recall Information
Study Finds Antibiotic-Resistant Staph in U.S. Food Supply
Formaldehyde in Popular Keratin Hair Products Concern State Regulators, Watch Dogs





Alvin Magalnick, A pharmacist at St Joseph’s Hospital discovered in
January of 2006 that patients on Tequin were getting elevated blood sugar levels. Monitoring diabetic patients ecpecially Black American’s & hispanics were getting even higher response to blood sugar levels & responded to the FDA, No response from the FDA.
Tequin warning was originally found in November of 2005 that patients that were diabetic, especially blacks & hispanics had very high incidences of elevating blood sugars over 400. Close monitoring showed that removal of Gatifloxin(Tequin)& switching to another floroquinolone did NOT show the same elevating circumstances.